HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Akira Shimatsu Selected Research

Osilodrostat

8/2020A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
1/2020Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
4/2016Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Akira Shimatsu Research Topics

Disease

13Obesity
01/2018 - 05/2007
11Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2015 - 01/2007
10Cardiovascular Diseases (Cardiovascular Disease)
01/2020 - 06/2008
9Neoplasms (Cancer)
08/2020 - 05/2003
8Heart Failure
06/2020 - 05/2007
7Inflammation (Inflammations)
10/2022 - 01/2013
7Insulin Resistance
06/2022 - 12/2007
7Weight Loss (Weight Reduction)
01/2016 - 06/2008
6Atherosclerosis
10/2022 - 06/2009
6Acromegaly
07/2022 - 01/2010
6Coronary Artery Disease (Coronary Atherosclerosis)
01/2022 - 12/2007
6Type 2 Diabetes Mellitus (MODY)
01/2021 - 09/2003
6Weight Gain
10/2018 - 04/2004
6Adenoma (Adenomas)
12/2017 - 01/2003
6Hypothyroidism
01/2017 - 08/2007
6Dyslipidemias (Dyslipidemia)
01/2015 - 01/2010
6Osteoporosis
01/2009 - 12/2007
5Diabetes Mellitus
06/2022 - 01/2005
5Myocardial Infarction
01/2022 - 05/2007
5Chronic Renal Insufficiency
01/2022 - 02/2011
5Pituitary Neoplasms (Pituitary Adenoma)
07/2021 - 01/2005
5Hypertension (High Blood Pressure)
06/2020 - 02/2009
5Hyperaldosteronism (Conn Syndrome)
12/2017 - 05/2012
4Glucose Intolerance
06/2022 - 12/2006
4Pituitary ACTH Hypersecretion
08/2020 - 09/2011
4Abdominal Obesity
01/2018 - 10/2006
4Hyperprolactinemia
04/2016 - 12/2010
4Hypertrophy
04/2010 - 03/2008
3Neuroendocrine Tumors (Neuroendocrine Tumor)
11/2021 - 01/2017
3Cushing Syndrome
04/2021 - 01/2020
3Graves Disease (Basedow Disease)
01/2021 - 01/2012
3Hypercholesterolemia
12/2016 - 01/2007
3Hyperglycemia
10/2016 - 09/2003
3Hashimoto Disease (Thyroiditis, Hashimoto)
01/2015 - 01/2010
3Prolactinoma (Prolactinomas)
06/2013 - 01/2003
3Cardiomegaly (Heart Hypertrophy)
11/2012 - 05/2007
3Thyrotoxicosis
01/2012 - 08/2007
2Thyroiditis
01/2021 - 03/2014
2Hyperplasia
08/2020 - 04/2013
2Adrenal Insufficiency (Adrenal Gland Hypofunction)
08/2020 - 04/2016
2Hyperthyroidism
12/2019 - 01/2012
2Hyperinsulinism (Hyperinsulinemia)
08/2018 - 09/2003

Drug/Important Bio-Agent (IBA)

12oxidized low density lipoproteinIBA
11/2016 - 01/2007
10Insulin (Novolin)FDA Link
07/2022 - 09/2003
10Glucose (Dextrose)FDA LinkGeneric
06/2022 - 04/2004
9Growth Hormone (Somatotropin)IBA
07/2022 - 01/2005
7AdiponectinIBA
10/2022 - 09/2003
7Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2007
7Immunoglobulin G (IgG)IBA
01/2021 - 01/2009
6Hydrocortisone (Cortisol)FDA LinkGeneric
04/2021 - 01/2010
6Adrenocorticotropic Hormone (ACTH)FDA Link
08/2020 - 01/2008
6Proteins (Proteins, Gene)FDA Link
12/2019 - 04/2004
6LDL Lipoproteins (beta Lipoproteins)IBA
11/2015 - 12/2007
6Eicosapentaenoic AcidIBA
01/2014 - 01/2007
5Insulin-Like Growth Factor I (IGF-1)IBA
07/2022 - 09/2009
5lanreotide (Somatuline)FDA Link
11/2021 - 01/2013
5AldosteroneIBA
12/2017 - 01/2010
5ProlactinIBA
03/2013 - 01/2003
4LeptinIBA
10/2022 - 04/2004
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2022 - 08/2007
4Hormones (Hormone)IBA
06/2022 - 05/2003
4AutoantibodiesIBA
12/2019 - 12/2010
4Thyroid HormonesIBA
08/2019 - 08/2007
4Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
01/2017 - 08/2013
4Lipoproteins (Lipoprotein)IBA
11/2016 - 01/2007
4Thyroxine (Levothyroxine)FDA LinkGeneric
01/2016 - 08/2007
4Indicators and Reagents (Reagents)IBA
01/2015 - 06/2008
4LDL CholesterolIBA
01/2013 - 06/2008
4Histone Acetyltransferases (Histone Acetyltransferase)IBA
01/2012 - 03/2008
4Transcription Factors (Transcription Factor)IBA
03/2010 - 01/2005
4Raloxifene Hydrochloride (Evista)FDA Link
03/2008 - 12/2007
3Triglycerides (Triacylglycerol)IBA
06/2022 - 01/2011
3Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
07/2021 - 01/2013
3Thyrotropin (Thyroid-Stimulating Hormone)FDA Link
07/2021 - 01/2005
3OsilodrostatIBA
08/2020 - 04/2016
3Hypoglycemic Agents (Hypoglycemics)IBA
06/2020 - 01/2010
3Vascular Endothelial Growth Factor CIBA
01/2020 - 01/2011
3Thyrotropin Receptors (Thyrotropin Receptor)IBA
12/2019 - 12/2007
3CholesterolIBA
11/2018 - 10/2008
3AdipokinesIBA
01/2018 - 09/2007
3Serum Amyloid A Protein (Serum Amyloid A)IBA
11/2016 - 11/2009
3polymeric prolactin (BPRL)IBA
04/2016 - 12/2010
3DNA (Deoxyribonucleic Acid)IBA
01/2013 - 03/2008
3CurcuminIBA
01/2012 - 03/2008
2Insulin-Like PeptidesIBA
07/2022 - 07/2017
2Somatostatin Receptors (Somatostatin Receptor)IBA
11/2021 - 05/2003
2SodiumIBA
01/2021 - 12/2007
2ipragliflozinIBA
01/2021 - 01/2020
2pegvisomantFDA LinkGeneric
02/2020 - 04/2016
2Somatotropin Receptors (Growth Hormone Receptor)IBA
02/2020 - 04/2016
2Steroid 11-beta-Hydroxylase (11 beta-Hydroxylase)IBA
01/2020 - 04/2013
2Messenger RNA (mRNA)IBA
12/2019 - 04/2010
2Amyloid (Amyloid Fibrils)IBA
01/2019 - 06/2009
2AlbuminsIBA
02/2018 - 01/2015
2Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
02/2018 - 01/2005
2LectinsIBA
01/2018 - 07/2010
2Cytochrome P-450 CYP11B2 (CYP11B2)IBA
12/2017 - 04/2013

Therapy/Procedure

20Therapeutics
04/2021 - 05/2007
3Glycemic Control
07/2022 - 02/2018
2Ligation
12/2019 - 02/2013